Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose oral minoxidil for androgenetic alopecia
ACTRN12618000606280Phase 2Completed
- Sponsor
- Sinclair Dermatology
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of minoxidil in androgenetic alopecia (AGA), Female Pattern Hair Loss (FPHL) and male pattern baldness (MPHL), sponsored by Sinclair Dermatology. Started Feb 2018; status: completed.
02
Drugs
minoxidil
03
Conditions
androgenetic alopecia (AGA)Female Pattern Hair Loss (FPHL)male pattern baldness (MPHL)
Beyond the preview
Go deeper on ACTRN12618000606280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000606280.